VariSeed 7.0 Treatment Planning Tool for Permanent Seed Implant Brachytherapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 5
Volume 11
Issue 5

PALO ALTO, California-Varian Medical Systems has released VariSeed 7.0, the company’s newest treatment planning software for permanent seed implant brachytherapy used in treating prostate cancer. VariSeed 7.0 gives physicians the ability to use real-time images generated during the implant procedure to deliver precise accurate doses, the company said in a news release.

PALO ALTO, California—Varian Medical Systems has released VariSeed 7.0, the company’s newest treatment planning software for permanent seed implant brachytherapy used in treating prostate cancer. VariSeed 7.0 gives physicians the ability to use real-time images generated during the implant procedure to deliver precise accurate doses, the company said in a news release.

Using VariSeed 7.0, radiation oncologists can generate a treatment plan, use it to implant the seeds, and see how the radiation dose will develop within the patient’s anatomy while the patient is still in the operating room. This allows for fine-tuning and more precise adjustments on the spot, the company said.

VariSeed 7.0 also introduces the ability to superimpose different kinds of diagnostic images such as MRI and single photon emission computed tomography (SPECT), which show the extent of disease, with CT and ultrasound images, which show anatomy and positioning. This enables physicians to adjust implants according to an individual patient’s disease characteristics.

VariSeed 7.0 is now available to new customers and as a software upgrade to clinics that already use VariSeed for planning and documenting prostate seed implant dosimetry.

Related Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content